PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Mission Therapeutics launches clinical trial for kidney disease therapy

MTX652 has advanced through preclinical regulatory toxicology studies and is ready for a phase 1 trial

Mission Therapeutics has been granted approval to take its lead USP30 deubiquitinating enzyme (DUB) inhibitor – MTX652 – into a clinical study.

The mitochondrial-associated DUB removes ubiquitin, which is what damaged mitochondria are labelled with. This inhibits the degradation of mitochondria, which can affect cell health. Mission has developed MTX652 to inhibit USP30, with the aim to enable appropriate degradation of dysfunctional mitochondria to preserve and improve cellular health.

Specific kidney cells are rich in mitochondria, making them highly vulnerable to injury if those mitochondria are not working properly. Mitochondrial dysfunction is strongly implicated in kidney injury and chronic kidney disease (CKD), while its quality is implicated in various other poorly treated conditions, such as idiopathic pulmonary fibrosis, muscular dystrophy and primary mitochondrial disease.

MTX652 has successfully advanced through preclinical regulatory toxicology studies, following candidate nomination last year. It is now ready to be progressed into the clinic and the phase 1 trial will evaluate the safety, tolerability and pharmacokinetics of MTX652 in over 60 participants given either a single or multiple doses.

Dr Suhail Nurbhai, chief medical officer of Mission Therapeutics, commented: “We are delighted that our lead programme is entering the clinic. Mission has built a groundbreaking platform for the discovery and development of first-in-class small molecule drugs that selectively target DUBs. MTX652 entering the clinic is a major milestone for the company and a tremendous achievement. We are excited to be taking this important next step.”

CKD affects an estimated 780 million people around the world. The NHS costs in 2009/10 were around £1.5bn, and are likely to be much more now, while estimated US Medicare costs for CKD are greater than $87bn.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026